secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001104659-24-083280
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics files investor presentation on Phase 2 SHINE results for CT1812 Alzheimer's study
--------------------------------------------------------------------------------

- Phase 2 proof-of-concept SHINE study of CT1812 in mild-to-moderate Alzheimer's disease.
- Results presented on July 29, 2024 via investor presentation filed as exhibit.
- No specific efficacy or safety endpoints disclosed in the 8-K filing text.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924083280/0001104659-24-083280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465924083280/tm2420336d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-083280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer